Latest Breaking News On - Cost among medicare beneficiaries - Page 1 : comparemela.com

Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021 Clostridioides difficile Infection With and Without Sepsis Presenting Author: Alpesh Amin, MD, MBA, Thomas Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California Irvine EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET DDW has made abstracts available on their website. About RBX2660 RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six con

United statesHeather guzziCourtney jonesLindsey rodgerLee jonesThomas mary cesarioKostenloser wertpapierhandelColleen kraftAlpesh aminChristine leeUs centers for diseaseAmerican society for gastrointestinal endoscopyUniversity of california irvineEmory university school of medicineIsland healthCommunications digital innovation